IP Library › Granted Patent US 12,540,324
Granted Patent B2
US 12,540,324 · App. 18/582,317 · Granted Feb 3, 2026

Composition for regulating production of interfering ribonucleic acid

Inventor: Bradley G. Thompson (Calgary, CA)
Assignee: Wyvern Pharmaceuticals Inc.
C12N15/1137C12N15/86C12N2310/141C12N2750/14143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,540,324
App. No.
18/582,317
Granted
Feb 3, 2026
Kind
B2
Abstract

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a complement or a factor. In some embodiments of the present disclosure, the target biomolecule is a complement such as complement C1q, complement C1r, complement C1s, complement C3 or complement C5. In some embodiments of the present disclosure, the target biomolecule is a factor such as Factor B, Factor D or Factor 10.

Claims (3)

1 . A composition that comprises a recombinant plasmid (RP) comprising a sequence of nucleotides that is SEQ ID NO. 2.

2 . The composition of claim 1 , wherein the RP is encased in a protein coat, a lipid vesicle, or any combination thereof.

3 . A composition that comprises a recombinant plasmid (RP) comprising a sequence of nucleotides that is SEQ ID NO. 10.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2025
From: THOMPSON, BRADLEY G.
To: WYVERN PHARMACEUTICALS INC.
Reel/Frame 072112/0908 →
Continuity (1)
Related Publication 20250263707A1 · Aug 21, 2025
References Cited (69)
US 9260756B2 · Rothenberg · 2016 [cited by examiner]
US 11085055B2 · Mallol et al. · 2021 [cited by applicant]
US 11162102B2 · Minshull et al. · 2021 [cited by applicant]
US 11530423B1 · Thompson · 2022 [cited by applicant]
US 11873505B2 · Thompson · 2024 [cited by applicant]
US 12018274B2 · Thompson · 2024 [cited by examiner]
US 20230399643A1 · Munk et al. · 2023 [cited by applicant]
US 20240026377A1 · Thompson · 2024 [cited by applicant]
CA 2721333A1 · 2009 [cited by applicant]
WO 2022142894A1 · 2022 [cited by applicant]
U.S. Appl. No. 18/745,792, filed Jun. 2024. [cited by examiner]
Keshari (et al. 2017. Inhibition of complement C5 protects against organ failure and reduces mortality in a baboon model of [cited by examiner]
Hao (et al. 2017. Discovery and Characterization of a Potent and Specific Peptide Ligand Targeting Endothelial Progenitor Cells and Endothelial Cells for Tissue Regeneration. ACS Chem. Biol. 12, 1075-1086) (Year: 2017). [cited by examiner]
Gao (et al. 2022. Elevated circASCC3 limits antitumor immunity by sponging miR-432-5p to upregulate C5a in non-small cell lung cancer. Canc. Lett 543:215774) (Year: 2022). [cited by examiner]
Wikipedia (Expression vector. Page archived Feb. 17, 2024. Available online at web.archive.org. Accessed on Jul. 8, 2024) (Year: 2024). [cited by examiner]
Cas (RA 101295. 2024. Available online at scifinder-n.cas.org. Accessed on Jul. 8, 2024) (Year: 2024). [cited by examiner]
Wikipedia (ETS2. 2024. Available online at web.archive.org. Accessed on Jul. 8, 2024) (Year: 2024). [cited by examiner]
Wikipedia (Complement system. Page edited May 25, 2024. Available online at Wikipedia.org. Accessed Jul. 8, 8, 2024) (Year: 2024). [cited by examiner]
Wikipedia (Plasmid. Page archived Jan. 19, 2024. Available online at web.archive.org. Accessed on Jul. 9, 2024.) (Year: 2024). [cited by examiner]
Ying (et al. 2008. The MicroRNA (miRNA): Overview of the RNA Genes that Modulate Gene Function. Mol. Biotechnol. 38:257-268) (Year: 2008). [cited by examiner]
Lam (et al. 2015. siRNA Versus miRNA as Therapeutics for Gene Silencing. Molec. Ther. Nuc. Ac. 4:e252) (Year: 2015). [cited by examiner]
Gorski (et al. 2017. RNA-based recognition and targeting: sowing the seeds of specificity. Nat. Rev. Mol. Cell Biol. 18:215-228) (Year: 2017). [cited by examiner]
O'Brien (et al. 2018. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front. Endocrinol. 9:402) (Year: 2018). [cited by examiner]
Xu (et al. 2019. miR-132 regulates the expression of synaptic proteins in APP/PS1 transgenic mice through C1q. Eur. J. Histochem. 63[3008]:69-76) (Year: 2019). [cited by examiner]
NCBI. 2025. “Homo sapiens complement C1q A chain [C1QA], transc. var. 1, 2, and 3, mRNA”; “Homo sapiens complement C1q B chain [C1QB], transc. var. 1 and 2, mRNA”; “Homo sapiens complement C1q C chain [C1QC], transc. va… [cited by examiner]
MiRbase [2025. “Stem-loop hsa-mir-132 Accession MI0000449”. Available online at miRbase.org. Accessed on May 20, 2025] (Year : 2025). [cited by examiner]
GeneCards [“C1q related genes—GeneCards Search Results” {limited to hits with term “C1q” in aliases and descriptions}. Available online at genecards.org. Accessed on May 20, 2025] (Year: 2025). [cited by examiner]
Momin et al.. 2021. Cells. 10, 3097, p. 1-21 (Year: 2021). [cited by applicant]
English Translation of WO 2022142894 (Year: 2022). [cited by applicant]
Wang (et al. 2021. Identification and characterization of miRNA expression profiles across five tissues in giant panda. Gene 769: 145206) (Year: 2021). [cited by applicant]
Chen et al. “miRDB: an online database for prediction of functional microRNA targets.” Nucleic acids research 48.D1 (2020): D127-D131. [cited by applicant]
Lynam-Lennon et al. “Low miR-187 expression promotes resistance to chemoradiation therapy in vitro and correlates with treatment failure in patients with esophageal adenocarcinoma.” Molecular Medicine 22 (2016): 388-397. [cited by applicant]
Wu et al. “MicroRNA-1 induces apoptosis by targeting prothymosin alpha in nasopharyngeal carcinoma cells.” Journal of biomedical science 18 (2011): 1-10. [cited by applicant]
Lei (et al. 2023. The Role and Potential Mechanism of Complement Factor D in Fibromyalgia Development. J. Pain Res. 16:4337-435) (Year: 2023). [cited by applicant]
Liu et al. “Regulatory mechanism of miR-722 on C5aR1 and its functions against bacterial inflammation in half-smooth tongue sole (Cynoglossus semilaevis).” International Journal of Biological Macromolecules 252 (2023): … [cited by applicant]
Zou et al. “Splenic RNA and microRNA mimics promote complement factor B production and alternative pathway activation via innate immune signaling.” The Journal of Immunology 196.6 (2016): 2788-2798. [cited by applicant]
Najib et al. “Viral hemorrhagic septicemia virus (VHSV) infection-mediated sequential changes in microRNAs profile of Epithelioma papulosum cyprini (EPC) cells.” Fish & Shellfish Immunology 61 (2017): 93-99. [cited by applicant]
Sadeghi et al. “IncRNA-miRNA-mRNA ceRNA network involved in sheep prolificacy: An integrated approach.” Genes 13.8 (2022): 1295. [cited by applicant]
NCBI C1R complement C1r (2025). [cited by applicant]
NCBI “Homo sapiens complement C3 [C3] mRNA and Homo sapiens complement 3 [C3] gene” (2025). [cited by applicant]
NCBI (Homo sapiens complement factor D [CFD], transcript variants 1 and 2, mRNA: NM_001928.4 and NM_001317335.2. Available online at NCBI.nim.nih.gov. Accessed on Jun. 5, 2025) (Year: 2025). [cited by applicant]
NCBI “Homo sapiens complement C5 [C5], transcript variants 1, 2, and 3, mRNA and Danio rerio microRNA 722 [dre-mir-722], microRNA” (2025). [cited by applicant]
MirGeneDb “10 microRNA genes of family MIR-722” (2025). [cited by applicant]
NCBI “Homo sapiens complement factor B (CFB), mRNA” (2025). [cited by applicant]
Stem-loop hsa-mir-99a-6p, etc (miRbase 2025). [cited by applicant]
NCBI (Homo sapiens coagulation factor X [F 10], transcript variants 1-3, mRNA, mRNA: NM_000504.4, NM_001312674.2, and NM 001312675.2. Available online at NCBI.nim.nih.gov. Accessed on Jun. 18, 2025) (Year: 2025). [cited by applicant]
Chen (et al. 2017. Overexpression of miR-24 Is Involved in the Formation of Hypocoagulation State after Severe Trauma by Inhibiting the Synthesis of Coagulation Factor X. Dis. Mar. 2017:3649693) (Year: 2017). [cited by applicant]
Zhang (et al. 2018. Coagulation Factor X Regulated by CASC2c Recruited Macrophages and Induced M2 Polarization in Glioblastoma Multiforme. Front, Immunol. 9:1557) (Year: 2018). [cited by applicant]
Collier (et al. 2022. Does bsa-miR-223-3p from platelet-derived extracellular vesicles regulate tissue factor expression in monocytic cells? Platelets 33[7]:1031-1042) (Year: 2022). [cited by applicant]
Bottoni et al. “Targeting BTK through microRNA in chronic lymphocytic leukemia.” Blood, The Journal of the American Society of Hematology 128.26 (2016): 3101-3112. [cited by applicant]
Brutons Tyrosine Kinase Genbank Sequence (2023). [cited by applicant]
Christensen et al. “Recombinant adeno-associated virus-mediated microRNA delivery into the postnatal mouse brain reveals a role for miR-134 in dendritogenesis in vivo.” Frontiers in neural circuits 3 (2010): 848,. [cited by applicant]
Bofill-De Ros et al. “Guidelines for the optimal design of miRNA-based shRNAs.” Methods 103 (2016): 157-166. [cited by applicant]
Denzler R et al. Impact of MicroRNA Levels, Target-Site Complementarity, and Cooperativity on Competing Endogenous RNA-Regulated Gene Expression. Mol Cell. Nov. 3, 2016;64(3):565-579. doi: 10.1016/j.molcel.2016.09.027 (… [cited by applicant]
Van den Berg, et al., pp. 1-12, Molecular Therapy—Nucleic Acids, vol. 5, 2016 (Year: 2016). [cited by applicant]
Gen Bank EGF Sequence (2023). [cited by applicant]
Nature (2010. Gene Expression, Scitable, Available online at Nature.com) <https://www.nature.com/scitable/topicpage/gene-expression-14121669> (2010). [cited by applicant]
Tritschler et al. “Concepts and limitations for learning developmental trajectories from single cell genomics.” Development 146.12 (2019): dev170506. [cited by applicant]
Ahmadzadeh et al. “BRAF mutation in hairy cell leukemia.” Oncology reviews 8.2 (2014): 253. [cited by applicant]
Patton et al. “Biogenesis, delivery, and function of extracellular RNA.” Journal of extracellular vesicles 4.1 (2015): 27494,. [cited by applicant]
Clark et al. “Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies.” Oncotarget 11.44 (2020): 4016. [cited by applicant]
NCBI Search results for SEQ ID No. 5 2024. [cited by applicant]
NCBI Nucleotide Sequence ALK Lingand, search performed Dec. 26, 2024 (2023). [cited by applicant]
NCBI Nucleotide Sequence ALK Receptor, search performed Dec. 26, 2024 (2023). [cited by applicant]
NCBI Nucleotide Sequence for PARP, search performed Dec. 26, 2024 (2024). [cited by applicant]
GenBank EGFR Sequence (2023). [cited by applicant]
Genbank FLT3 Sequence (2024). [cited by applicant]
Kondratov et al. “Direct head-to-head evaluation of recombinant adeno-associated viral vectors manufactured in human versus insect cells.” Molecular Therapy 25.12 (2017): 2661-2675. [cited by applicant]
Wang et al. “Adeno-associated virus vector as a platform for gene therapy delivery”. Nat Rev Drug Discov. May 2019: 18(5):358-378. (Year: 2019). [cited by applicant]